Global NGS-Based RNA-Sequencing Market – Industry Trends and Forecast to 2029

Market Analysis and Size

NGS-based RNA-seq is widely employed for sophisticated and comprehensive genomic insights in both standard and non-traditional applications. The growing demand for better sequencing-based diagnostics has fueled the development of novel sequencing technologies. As a result, demand for technologies like high-throughput sequencers and portable units has skyrocketed. The market for NGS-based RNA-seq is increasing due to a number of causes, including technological developments in RNA-seq products, the advantages of RNA-seq over microarray technology, rapid expansion in research activities, an increase in RNA-seq awards, and a high need for precision medicine.

Data Bridge Market Research analyses that the NGS-based RNA-sequencing market which was USD 2.44 billion in 2021, would rocket up to USD 10.42 billion by 2029, and is expected to undergo a CAGR of 19.90% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation      

Market Definition

The term "next-generation sequencing," sometimes known as "high-throughput sequencing," refers to a variety of current sequencing technologies. In the future years, the market is likely to rise due to an increased focus on genetic studies and gene-based medicinal technologies.

NGS-Based RNA-Sequencing Market Dynamics

Drivers

• Increasing R&D activities

Increased research activity, rising demand for precision medicine, and growing benefits of RNA-Seq In the projected period of 2022-2029, the increasing number of RNA-Seq grants is expected to boost the growth of the NGS-based RNA-sequencing market. Increasing levels of investment in cancer research as well as the agriculture sector, on the other hand, will propel the NGS-based RNA-sequencing market forward over the projection period.

• Demand of NGS sequencing

The demand for next-generation sequencing technology increased dramatically after its launch. It is widely utilised in both traditional and non-traditional applications to obtain advanced and comprehensive genetic insights. The growing demand for enhanced sequencing-based diagnostics has fueled the development of brand-new sequencing technologies. As a result, equipment like robust high-throughput sequencers and portable units have exploded in popularity.

• Technological advancements in sequencing platforms

Continuous advancements in sequencing technology have allowed for the development of efficient, portable, and easy-to-use NGS sequencers that give speedy and exact results while minimising turnaround times. As a result, leading companies are continually focused on investing in research activities for new product development to improve their positions in this high-growth industry.

Opportunities

In recent years, advances in next-generation sequencing, like paired-end (PE) sequencing, have enabled library preparation to produce twice as many reads simultaneously. Sequencing both ends of DNA fragments in the library and aligning forward and reverse reads as reading pairs are used in this procedure. Sequences with more accurate read alignment and, hence, the ability to detect indels, which is not achievable with single-read data, have also been enabled by the approaches. The paired-end strategy is the most modern and well-liked technique among the researchers.

Restraints/Challenges

In the forecast period, the lack of qualified specialists, lack of diagnostic testing standards, and instability of RNA under normal settings are anticipated to hamper the expansion of the NGS-based RNA-sequencing market. Furthermore, the rise of service provider companies that have joined the market and are offering next-generation sequencing at a lower cost.

This NGS-based RNA-sequencing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the NGS-based RNA-sequencing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Covid-19 impact on NGS-Based RNA-Sequencing Market

Several researchers have used next-generation sequencing as an exploratory tool in the fight against the COVID-19 pandemic. In order to keep up to speed on infection dynamics and viral pathogenesis of the SARS-CoV-2 virus, accurate RNA sequencing is required. The research was conducted to better comprehend the virus's ever-changing features and epidemiology across diverse countries using single-cell RNA sequencing, stranded RNA sequencing, and ultra-low input RNA sequencing. Based on a genome-wide RNA sequencing dataset, a detailed research of the SARS-CoV-2 virus was carried out in order to discover the molecular mechanisms and hub genes. This has considerably enhanced clinical research and development activities using NGS as the foundation for innovation. Thus, in the context of the ongoing pandemic, the NGS-based RNA-Sequencing market is projected to be positively impacted by COVID-19.

Recent Development

• In May 2021, SEQuoia RiboDepletion Kit for NGS, developed by Bio-Rad Laboratories, Inc., removes unnecessary ribosomal RNA from the RNA-sequencing library and enhances test efficiency.
• In March 2022, Element Biosciences Inc. has released the Element AVITI System, a benchtop sequencer that provides an unmatched mix of performance, affordability, and flexibility. A benchtop NGS instrument and related consumables make up this system.

Global NGS-Based RNA-Sequencing Market Scope

The NGS-based RNA-sequencing market is segmented on the basis of type, skin site and diseases. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product and Service

• Sample Preparation Products
• Sequencing Platforms and Consumables
• Sequencing Services
• Data Analysis, Storage, and Management

Technology

• Sequencing by Synthesis
• Ion Semiconductor Sequencing
• Single-molecule Real-time Sequencing
• Nanopore Sequencing

Application

• Expression Profiling Analysis
• Small RNA Sequencing
• De Novo Transcriptome Assembly
• Variant Calling and Transcriptome Epigenetics

End User

• Research and Academia
• Hospitals and Clinics
• Pharmaceutical and Biotechnology Companies
• Other End Users

NGS-based RNA-sequencing Market Regional Analysis/Insights

The NGS-based RNA-sequencing market is analysed and market size insights and trends are provided by country, type, skin site and diseases as referenced above.

The countries covered in the NGS-based RNA-sequencing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominating the NGS-based RNA-sequencing market due to the increasing initiatives and funds from the government for genomics research, growing occurrences of chronic diseases, adoption of RNA-Seq products.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the increasing levels of investment for research activities and occurrence of better health facilities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and NGS-based RNA-sequencing Market Share Analysis

The NGS-based RNA-sequencing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to NGS-based RNA-sequencing market.

Some of the major players operating in the NGS-based RNA-sequencing market are:

• Illumina Inc. (US)
• Thermo Fischer Scientific Inc. (US)
• Oxford Nanopore Technologies plc (UK)
• Agilent Technologies, Inc. (US)
• BGI (China)
• PerkinElmer Inc. (US)
• QIAGEN (Germany)
• Eurofins Scientific (Luxembourg)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Takara Bio Inc. (Japan)
• GENEWIZ, Inc. (US)
• Hamilton Company (US)
• Macrogen Inc. (South Korea)
• Zymo Research Corporation (US)
• Tecan Trading AG (Switzerland) 

SKU-53010